Eugenio Galli

Scopus Publications

Neuronal injury biomarkers GFAP and neurofilament light chains (NfL) are associated with neurotoxicity and endothelial dysfunction in adult patients treated with antiCD19 CART cells
Eugenio Galli, Anna Modoni, Luca Battistini, Monica Rossi, Gisella Guerrera, Ilaria Pansini, Alessandro Corrente, Stefan Hohaus, Patrizia Chiusolo, Federica Sorà, Paolo Calabresi, Simona Sica
Clinical and Experimental Medicine, 2026
Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 have revolutionized the treatment of B-cell malignancies, but their use is frequently complicated by immune effector cell-associated neurotoxicity syndrome (ICANS). The underlying mechanisms include endothelial dysfunction, blood–brain barrier disruption, and neuroinflammation. Circulating biomarkers of neuronal and astroglial injury, such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), may provide insight into ICANS pathophysiology and serve as predictive tools. We conducted a retrospective study of 34 adult patients treated with anti-CD19 CAR-T cells for B-cell malignancies. Serum NfL and GFAP were measured at infusion (day 0) and day 7 using ultrasensitive immunoassays. Baseline GFAP and NfL levels correlated with endothelial activation markers, including mEASIX and lactate dehydrogenase, but not with demographic variables. ICANS of any grade occurred in 34% of patients, and baseline levels of both GFAP and NfL were significantly associated with ICANS development and with steroid requirement. In contrast, changes in biomarker concentrations between day 0 and day 7 were not statistically significant overall, although individual variability was observed. At day 7, elevated NfL levels correlated with laboratory evidence of disseminated intravascular coagulation (DIC), prolonged clotting time, and C-reactive protein elevation. GFAP elevation was also linked to coagulopathy, particularly prolonged clotting time. Baseline serum levels of GFAP and NfL predict the risk of ICANS and the need for corticosteroid intervention in CAR-T-treated adults, supporting their role as biomarkers of pre-existing neuronal susceptibility. Furthermore, their association with coagulation abnormalities underscores the interplay between neurotoxicity, endothelial stress, and systemic inflammation. These findings highlight the potential clinical utility of integrating GFAP and NfL into multimodal biomarker panels to improve risk stratification and management of CAR-T neurotoxicity.
Organ-specific local cytokine release syndrome after anti-CD19 CAR-T therapy with salivary gland involvement: a case report, literature review, and a diagnostic alert for tocilizumab-associated cervical swelling
Roberto Maggi, Enrico Federico Ricciuti, Eugenio Galli, Federica Sorà, Antonella Fiorita, Simona Sica, Patrizia Chiusolo
Annals of Hematology, 2026
Background. Cytokine release syndrome (CRS) is the most frequent toxicity after chimeric antigen receptor T-cell (CAR-T) therapy and typically presents as a systemic inflammatory syndrome. In recent years, a localized form of CRS (L-CRS), most commonly involving the craniocervical region, has been increasingly recognized. L-CRS may occur with or without overt local tumor involvement and can progress to airway impairment, requiring prompt recognition and treatment. Case presentation. We report two cases of patients with refractory diffuse large B-cell lymphoma (DLBCL) treated with anti-CD19 CAR-T therapy who developed abrupt, painful bilateral parotid and/or submandibular gland swelling (left predominance) early after infusion, following systemic CRS treated with tocilizumab. Infectious, obstructive, and autoimmune causes were excluded; ultrasound findings were compatible with inflammatory glandular changes. Given rapid progression and concern for airway patency, corticosteroids were administered with prompt clinical resolution. Literature review and diagnostic alert. We provide an overview of published L-CRS with craniocervical presentations (Table 1). Similar acute swelling temporally related to tocilizumab has been reported in other settings. In such cases, differential diagnostics of L-CRS vs. a tocilizumab-associated infusion-related/hypersensitivity reaction needs to be carried out. Conclusion. L-CRS is a clinically relevant and potentially severe complication of CAR-T therapy that may involve salivary glands even without cervical tumor burden. Clinicians should also consider drug-related reactions, particularly when cervical swelling occurs shortly after tocilizumab administration.
Vascular inflammation in patients undergoing anti-CD19 chimeric antigen receptor-T cells for haematologic malignancies: a call for cardiovascular surveillance
Massimiliano Camilli, Andrea Guarneri, Lucia Leccisotti, Federico Ballacci, Marcello Viscovo, Eugenio Galli, Luca Maggio, Lorenzo Tinti, Priscilla Lamendola, Stefan Hohaus, Simona Sica, Federica Sorà, Patrizia Chiusolo, Gaetano Antonio Lanza, Giovanna Liuzzo, Francesco Burzotta, Alessandro Giordano, Filippo Crea, Antonella Lombardo, Giorgio Minotti
European Heart Journal, 2026
Abstract
Beyond comorbidities: CAR-T as a safe and effective option in frail patients with second-line DLBCL
Eugenio Galli
Recenti Progressi in Medicina, 2026
La terapia con CAR-T anti-CD19 è oggi standard in seconda linea per DLBCL recidivato/refrattario, ma la gestione dei pazienti fragili resta controversa per il rischio di tossicità e mortalità non da recidiva. Presentiamo il caso di un uomo di 74 anni con DLBCL ad alto rischio e numerose comorbilità, refrattario alla prima linea, trattato con axicabtagene ciloleucel. Nonostante un punteggio elevato di CIRS e HCT-CI, il paziente non ha sviluppato tossicità severe: solo CRS di grado 1 ben controllato con tocilizumab precoce e citopenia transitoria. Ha ottenuto e mantenuto una risposta completa a 14 mesi dall’infusione. L’esperienza conferma, in linea con i dati ALYCANTE e di coorti real-life, che le comorbilità non predicono da sole gli eventi avversi gravi. Parametri dinamici come ECOG, mEASIX e CAR-HEMATOTOX si rivelano più utili. Escludere pazienti solo per fragilità o comorbilità rischia di privarli di un’opzione potenzialmente curativa.
Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a Real-World Setting
Andrea Mattozzi, Eugenio Galli, Francesco Autore, Ilaria Pansini, Patrizia Chiusolo, Simona Sica, Federica Sorà
Mediterranean Journal of Hematology and Infectious Diseases, 2026
Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study
Eugenio Galli, Roberta Di Blasi, Alice Di Rocco, Caterina Cristinelli, Ilaria Pansini, Côme Bommier, Alessandro Corrente, Ilenia De Bernardis, Marcello Viscovo, Stefan Hohaus, Anna Modoni, Federica Sorà, Patrizia Chiusolo, Maurizio Martelli, Simona Sica, Catherine Thieblemont
Blood Advances, 2025
This study aims to evaluate the impact of levetiracetam (LVT) prophylaxis on the incidence and severity of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients undergoing anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for LBCL (large B-cell lymphoma). A propensity score–matched cohort of 254 patients was analyzed, comparing those receiving LVT prophylaxis (LTV-yes) with those not receiving it (LTV-no), in a 1:1 ratio. The results showed no significant difference in the occurrence of ICANS of any grade between the 2 groups (32.3% in LVT-no vs 37.1% in LVT-yes; P = .29), or in severe ICANS (grades 2-4, 15.1% vs 16.1% [P = .80]; grade 3-4, 7.9% vs 9.7% [P = .71]). The use of LVT was associated with a higher incidence of early immune effector cell–associated hematotoxicity (ICAHT), with grade 2 to 4 ICAHT occurring in 37.3% vs 63.9% (P &lt; .001) of patients in the LVT-no and LVT-yes groups, respectively. Overall survival and progression-free survival did not differ significantly between the 2 groups (P = .337 and .670). Nonrelapse mortality rates were comparable (P = .77). These findings suggest that routine use of LVT as prophylaxis for ICANS in CAR-T therapy is not effective, and further research is needed to refine its role in selected populations or after ICANS treatment.
Tracking Inflammation in CAR-T Therapy: The Emerging Role of Serum Amyloid A (SAA)
Ilaria Pansini, Eugenio Galli, Alessandro Corrente, Marcello Viscovo, Silvia Baroni, Nicola Piccirillo, Patrizia Chiusolo, Federica Sorà, Simona Sica
Cancers, 2025
Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of relapsed/refractory large B-cell lymphoma (LBCL), but its administration is often complicated by cytokine release syndrome (CRS). Interleukin-6 (IL-6) is widely used to monitor CRS, though its clinical value diminishes after tocilizumab administration. We aimed to evaluate serum amyloid A (SAA), a dynamic acute-phase reactant, as a treatment-independent biomarker of inflammation and toxicity in CAR-T recipients. Methods: This retrospective study included 43 adults with LBCL treated with axicabtagene ciloleucel. SAA and other inflammatory markers were assessed from lymphodepletion through day +11 post-infusion. CRS and ICANS were graded per ASTCT criteria. Statistical analyses included Mann–Whitney U tests, Spearman’s correlation, and ROC curve analysis to evaluate predictive performance. Results: SAA levels peaked at day +4 and normalized by day +11, displaying wave-like kinetics. Levels were significantly higher in patients with any-grade CRS at early timepoints but showed no association with ICANS. SAA correlated strongly with CRP, suPAR, sST2, fibrinogen, ferritin, procalcitonin, and IL-6. Compared to IL-6, SAA was more predictive of CRS at day +2 and +4, and unaffected by tocilizumab. Baseline SAA also correlated with the mEASIX score, suggesting linkage to endothelial stress. Non-responders at 3-month PET had higher baseline SAA than responders (196.0 vs. 17.7 mg/L, p = 0.036), with ROC analysis yielding an AUC of 0.74 and an optimal threshold of 79.8 mg/L. Conclusions: SAA is a robust and dynamic marker of systemic inflammation, with potential utility in both toxicity monitoring and response prediction in the CAR-T setting. Its independence from IL-6 modulation positions it as a promising biomarker for future integration into clinical algorithms.
Deciphering the Complex Intertwining Between Cytopenia and Transfusion Needs After CAR-T-Cell Therapy for B-Cell Malignancies
Claudio Pellegrino, Eugenio Galli, Patrizia Chiusolo, Rossella Ladiana, Caterina Giovanna Valentini, Marcello Viscovo, Federica Sorà, Simona Sica, Luciana Teofili
Life, 2025
Immune-effector-cell-associated hematotoxicity has emerged as the most common CAR-T-cell-related complication in the real-world setting. Therefore, transfusion of blood components remains unavoidable in many patients treated with CAR-T cells to alleviate symptomatic anemia and prevent major bleeding events. This study investigates predictive factors associated with the transfusion requirement in patients receiving anti-CD19 CAR-T-cell therapy for B-cell malignancies in a real-world setting and the potential correlation between transfusion needs, ICAHT, and long-term survival outcomes. Among 90 investigated patients, 51 (56.7%) received at least one transfusion in the three months post-infusion (33.4% received only RBC concentrates, and 23.4% received both RBC and platelet transfusions). The highest transfusion needs occurred in the first month post-infusion, with 50 transfused patients (55.5%). Early transfusion-requiring cytopenia was associated with pre-infusion altered bone marrow function, patients-related factors, including female sex, and acute inflammatory toxicities. The incidence of late cytopenia was mainly predicted by the need for pre-infusion transfusion support. Patients receiving platelet transfusions were characterized by an inferior progression-free (p = 0.013) and overall survival (p = 0.005). CAR-T-cell-treated patients can experience a high transfusion burden, impairing their quality of life, potentially affecting survival outcomes, and resulting in overutilization of clinical resources
High-dose thiotepa may induce inappropriate secretion of antidiuretic hormone syndrome (SIADH) during conditioning treatment for allogeneic stem cell transplantation
Maria Assunta Limongiello, Elisabetta Metafuni, Sabrina Giammarco, Eugenio Galli, Federica Sorà, Francesco Autore, Silvia Baroni, Patrizia Chiusolo, Simona Sica
International Journal of Hematology, 2025
Predictors of Neurotoxicity in a Large Cohort of Italian Patients Undergoing Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy
Anna Modoni, Catello Vollono, Eugenio Galli, Luca Capriati, Federica Sorà, Stefan Hohaus, Serenella Servidei, Nicola Piccirillo, Paolo Calabresi, Simona Sica
Brain and Behavior, 2025
BackgroundAnti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy is an innovative and effective treatment for patients with B‐cell hematological malignancies. Despite its high efficacy, it has been associated with the development of acute toxicities that can be severe or even fatal. Indeed, cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) can induce significant morbidity and require close monitoring. Identification of clinical and laboratory markers able to predict the occurrence of ICANS may allow prompt recognition and more effective management strategies.MethodsHere, we report a retrospective study on a cohort of 81 Italian adult patients treated in our hospital between September 2019 and April 2024. We reviewed all clinical, demographic, laboratory, and neurophysiological data in order to identify potential predictors.ResultsThe results of the multivariate analysis confirmed that ICANS typically occurred less frequently in younger patients, especially when treated with 41BB co‐stimulated CAR‐T. Baseline EEG abnormalities are confirmed to be a fundamental predictor of neurotoxicity. Interestingly, we identified GammaGT as a new, statistically significant marker of ICANS. This represents a novel finding, probably related to the important role of GammaGT also in neuroinflammation.ConclusionsOur results need to be confirmed in a larger cohort of patients in order to eventually be integrated into current clinical practice and management of patients undergoing CAR‐T.
Frail is not fail: Limited impact of comorbidities on non-relapse mortality and safety in patients with LBCL treated with CAR-T
Eugenio Galli, Roberta Di Blasi, Ilaria Pansini, Caterina Cristinelli, Come Bommier, Ilenia De Bernardis, Alessandro Corrente, Marcello Viscovo, Luca Montini, Patrizia Chiusolo, Stefan Hohaus, Federica Sorà, Catherine Thieblemont, Simona Sica
British Journal of Haematology, 2025
CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT cellular therapy and immunobiology working party
Nina Worel, Jarl E. Mooyaart, Jorinde D. Hoogenboom, Michael Daskalakis, Jean-Jacques Tudesq, Ron Ram, Vladan Vucinic, Stefania Bramanti, Lucía López Corral, Emma Nicholson, Robert Zeiser, Friedrich Stölzel, Eugenio Galli, Simona Pagliuca, Eva Wagner-Drouet, Friso Calkoen, Christian Chabannon, Florent Malard, Annalisa Ruggeri, Jürgen Kuball
Bone Marrow Transplantation, 2025
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study
Mirko Farina, Simona Bernardi, Michele Malagola, Alessandro Re, Eugenio Galli, Marcello Riva, Ilaria Cutini, Alessandro Leoni, Massimo Martino, Silvia Ferrari, Giorgia Battipaglia, Mattia Novo, Maurizio Musso, Giovanni Grillo, Stella Santarone, Mauro Krampera, Andrea Aroldi, Nicola Polverelli, Luca Arcaini, Besjana Xhahysa, Daniele Avenoso, Maria Chiara Tisi, Patrizia Chiusolo, Domenico Russo
Bone Marrow Transplantation, 2025
VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation
Francesco Autore, Daniele Mannina, Federica Lessi, Eugenio Galli, Stefania Oliva, Daniele Derudas, Claudia Giannotta, Claudia Crippa, Katia Mancuso, Magda Marcatti, Idanna Innocenti, Rita Mazza, Stefania Bramanti, Luca Laurenti
Hematological Oncology, 2025
Complete remission induced by rituximab-lenalidomide, following CAR-T cell failure, is not associated with CAR-T cell re-expansion in the peripheral blood
Lucrezia De Marchi, Eugenio Galli, Patrizia Chiusolo, Maria Antonietta Irno Consalvo, Lucia Cardillo, Massimiliano Postorino, Adriano Venditti, Federica Sorà, Maria Christina Cox
Annals of Hematology, 2025
COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: what is the role of anti-CD20 antibody?
Francesco Autore, Andrea Visentin, Marina Deodato, Candida Vitale, Eugenio Galli, Alberto Fresa, Rita Fazzi, Alessandro Sanna, Jacopo Olivieri, Ilaria Scortechini, Maria Ilaria Del Principe, Paolo Sportoletti, Idanna Innocenti, Marta Coscia, Alessandra Tedeschi, Livio Trentin, Anna Candoni, Alessandro Busca, Livio Pagano, Luca Laurenti
Blood Advances, 2025
Prolonged cytopenia following third-line CAR-T therapy in a heavily chemotherapy-pretreated patient
Eugenio Galli
Recenti Progressi in Medicina, 2025
Toxicities Associated with CAR-T Cell Therapies
Ugo Testa, Germana Castelli, Elvira Pelosi, Eugenia Galli, Patrizia Chiusolo
Mediterranean Journal of Hematology and Infectious Diseases, 2025
Baseline Tumor Burden Assessed With AI-Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR-T in Aggressive B-Cell Lymphoma
Eugenio Galli, Andrea Guarneri, Federica Sorà, Marcello Viscovo, Ilaria Pansini, Elena Maiolo, Eleonora Alma, Salvatore Annunziata, Simona Sica, Lucia Leccisotti, Stefan Hohaus
Hematological Oncology, 2025
Predicting therapy-related myeloid neoplasms after CAR-T with the Clonal Haematopoiesis Risk Score (CHRS)
Eugenio Galli, Monica Rossi, Ilaria Pansini, Marcello Viscovo, Tanja Malara, Maria Colangelo, Eleonora Alma, Caterina Giovanna Valentini, Luciana Teofili, Stefan Hohaus, Simona Sica, Federica Sorà, Patrizia Chiusolo
British Journal of Haematology, 2025
First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies
Francesco Autore, A. Tedeschi, G. Benevolo, V. Mattiello, E. Galli, N. Danesin, R. Rizzi, J. Olivieri, E. Cencini, B. Puccini, I. Ferrarini, D. Marino, M. Bullo, B. Rossini, M. Motta, I. Innocenti, A. Fresa, L. Stirparo, D. Petrilli, R. Pasquale, P. Musto, G. Scapinello, A. Noto, V. Peri, G. Zamprogna, S. Hohaus, A. M. Frustaci, F. Piazza, S. Ferrero, L. Laurenti
American Journal of Hematology, 2025
Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study
Massimiliano Camilli, Marcello Viscovo, Tamara Felici, Luca Maggio, Federico Ballacci, Giacomo Carella, Alice Bonanni, Priscilla Lamendola, Lorenzo Tinti, Antonio Di Renzo, Giulia Coarelli, Eugenio Galli, Giovanna Liuzzo, Francesco Burzotta, Rocco Antonio Montone, Federica Sorà, Simona Sica, Stefan Hohaus, Gaetano Antonio Lanza, Filippo Crea, Antonella Lombardo, Giorgio Minotti
Cardio Oncology, 2024
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience
Idanna Innocenti, Antonio Mosca, Annamaria Tomasso, Andrea Galitzia, Lydia Scarfò, Francesca Morelli, Eugenio Galli, Francesca Martini, Eugenio Sangiorgi, Roberta Laureana, Giulia Benintende, Veronica Mattiello, Sabrina Chiriu, Maria I. Del Principe, Giulia Zamprogna, Massimo Gentile, Enrica A. Martino, Emilia Cappello, Maria C. Montalbano, Giuliana Farina, Vanessa Innao, Luca Stirparo, Caterina Patti, Paolo Sportoletti, Alberto Fresa, Gioacchino Catania, Marta Coscia, Silvia Bellesi, Alessandra Tedeschi, Alessandro Sanna, Andrea Visentin, Francesco Autore, Raffaella Pasquale, Livio Trentin, Marzia Varettoni, Paolo Ghia, Roberta Murru, Luca Laurenti
Hemasphere, 2024
CAR-T treatment is safe and effective in adult patients with Down syndrome and B-cell acute lymphoblastic leukemia (B-ALL)
Eugenio Galli, Alessandro Corrente, Patrizia Chiusolo, Simona Sica, Federica Sorà
Bone Marrow Transplantation, 2024
Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT
Urban Novak, Jarl E. Mooyaart, Michael Daskalakis, Christof Scheid, Ludovic Gabellier, Ibrahim Yakoub-Agha, Ron Ram, Edouard Forcade, Lucía López-Corral, Emma Nicholson, Eugenio Galli, Friedrich Stölzel, Wolfgang Bethge, Eva Maria Wagner-Drouet, Jorinde D. Hoogenboom, Stephan Mielke, Caroline Arber, Federico Simonetta, Christian Chabannon, Jürgen Kuball, Annalisa Ruggeri, Florent Malard
Bone Marrow Transplantation, 2024
Coagulopathy in CAR-T: Critical concern or mere blip?
Eugenio Galli, Federica Sorà, Elena Rossi
British Journal of Haematology, 2024
CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation
John Donald Marra, Eugenio Galli, Sabrina Giammarco, Elisabetta Metafuni, Gessica Minnella, Federica Fosso, Sara Marietti, Simona Sica, Federica Sorà, Patrizia Chiusolo
European Journal of Haematology, 2024
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study
Francesco Autore, Andrea Visentin, Marina Deodato, Candida Vitale, Eugenio Galli, Alberto Fresa, Rita Fazzi, Alessandro Sanna, Jacopo Olivieri, Ilaria Scortechini, Maria Ilaria Del Principe, Paolo Sportoletti, Luana Schiattone, Nilla Maschio, Davide Facchinelli, Francesco Marchesi, Marta Coscia, Alessandra Tedeschi, Livio Trentin, Idanna Innocenti, Anna Candoni, Alessandro Busca, Livio Pagano, Luca Laurenti
American Journal of Hematology, 2024
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
Annalisa Chiappella, Beatrice Casadei, Patrizia Chiusolo, Alice Di Rocco, Silva Ljevar, Martina Magni, Piera Angelillo, Anna Maria Barbui, Ilaria Cutini, Anna Dodero, Francesca Bonifazi, Maria Chiara Tisi, Stefania Bramanti, Maurizio Musso, Mirko Farina, Massimo Martino, Mattia Novo, Giovanni Grillo, Francesca Patriarca, Giulia Zacchi, Mauro Krampera, Martina Pennisi, Eugenio Galli, Maurizio Martelli, Andrés J. M. Ferreri, Silvia Ferrari, Riccardo Saccardi, Anisa Bermema, Anna Guidetti, Rosalba Miceli, Pier Luigi Zinzani, Paolo Corradini
Leukemia, 2024
Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up
Anna M. Raiola, Carmen Di Grazia, Alida Dominietto, Stefania Bregante, Sabrina Giammarco, Riccardo Varaldo, Federica Sorà, Elisabetta Metafuni, Maria A. Limongiello, Antonella Laudisi, Monica Passannante, Eugenio Galli, Massimiliano Gambella, Simona Sica, Andrea Bacigalupo, Emanuele Angelucci, Patrizia Chiusolo
Blood Advances, 2024
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy
Eugenio Galli, Elisabetta Metafuni, Carlo Gandi, Maria Assunta Limongiello, Sabrina Giammarco, Andrea Mattozzi, Rosaria Santangelo, Andrea Bacigalupo, Federica Sorà, Patrizia Chiusolo, Simona Sica
European Journal of Haematology, 2024
Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity
Eugenio Galli, Maria Assunta Limongiello, Elisabetta Metafuni, Sabrina Giammarco, Alberto Fresa, Nicola Piccirillo, Maria Bianchi, Luca Laurenti, Federica Sorà, Patrizia Chiusolo, Simona Sica
American Journal of Hematology, 2024
Unlocking Predictive Power: Quantitative Assessment of CAR-T Expansion with Digital Droplet Polymerase Chain Reaction (ddPCR)
Eugenio Galli, Marcello Viscovo, Federica Fosso, Ilaria Pansini, Giacomo Di Cesare, Camilla Iacovelli, Elena Maiolo, Federica Sorà, Stefan Hohaus, Simona Sica, Silvia Bellesi, Patrizia Chiusolo
International Journal of Molecular Sciences, 2024
Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management
John Donald Marra, Filippo Frioni, Gessica Minnella, Monica Rossi, Tanja Malara, Silvia Bellesi, Elena Maiolo, Daniela Orteschi, Eugenio Galli, Andrea Bacigalupo, Livio Pagano, Simona Sica, Gina Zini, Patrizia Chiusolo
Annals of Hematology, 2024
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?
Francesco Autore, Stefania Bramanti, Federica Lessi, Idanna Innocenti, Eugenio Galli, Serena Rocchi, Rossella Ribolla, Daniele Derudas, Stefania Oliva, Paola Stefanoni, Magda Marcatti, Angelo Schenone, Giorgio La Nasa, Claudia Crippa, Elena Zamagni, Marcello Riva, Rita Mazza, Daniele Mannina, Simona Sica, Andrea Bacigalupo, Luca Laurenti
Haematologica, 2024
Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T-cells (CAR-T): A comprehensive review on incidence, risk factors and current management
Eugenio Galli, Alberto Fresa, Silvia Bellesi, Elisabetta Metafuni, Elena Maiolo, Ilaria Pansini, Filippo Frioni, Francesco Autore, Maria Assunta Limongiello, Idanna Innocenti, Sabrina Giammarco, Patrizia Chiusolo, Gina Zini, Federica Sorà
European Journal of Haematology, 2024
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-t Cells
Eugenio Galli, Filippo Frioni, Tanja Malara, Enrico Attardi, Silvia Bellesi, Stefan Hohaus, Simona Sica, Federica Sorà, Patrizia Chiusolo
Mediterranean Journal of Hematology and Infectious Diseases, 2024
The impact of donor-specific antibodies’ presence on the outcome post-allogeneic hematopoietic stem cell transplantation: a survey from a single center
Simona Sica, Elisabetta Metafuni, Filippo Frioni, Maria Assunta Limongiello, Eugenio Galli, Federica Sorà, Andrea Bacigalupo, Elvira Poggi, Mariano Antonio Feccia, Annarita Manfreda, Patrizia Chiusolo, Sabrina Giammarco
Frontiers in Oncology, 2024
Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience
Idanna Innocenti, Alberto Fresa, Annamaria Tomasso, Michela Tarnani, Laura De Padua, Giulia Benintende, Raffaella Pasquale, Eugenio Galli, Francesca Morelli, Diana Giannarelli, Francesco Autore, Luca Laurenti
Cancers, 2023
Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic
Eugenio Galli, Alice Di Rocco, Ilaria Pansini, Federico Frondizi, Martina Di Palma, Elisabetta Metafuni, Nicola Piccirillo, Maria Bianchi, Antonella Cingolani, Giovanni Fernando Torelli, Stefan Hohaus, Patrizia Chiusolo, Anna Paola Iori, Simona Sica, Maurizio Martelli, Federica Sorà
Bone Marrow Transplantation, 2023
The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity
Eugenio Galli, Silvia Bellesi, Ilaria Pansini, Giacomo Di Cesare, Camilla Iacovelli, Rosalia Malafronte, Elena Maiolo, Patrizia Chiusolo, Simona Sica, Federica Sorà, Stefan Hohaus
British Journal of Haematology, 2023
Spontaneous resolution of “therapy-related myelodysplasia” occurred after treatment with CAR-T cells: All that glitters is not gold
Filippo Frioni, Eugenio Galli, Federica Sorà, Gina Zini, Simona Sica, Patrizia Chiusolo
International Journal of Laboratory Hematology, 2023
Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis
J. D. Marra, E. Galli, S. Giammarco, P. Chiusolo, E. Metafuni, F. Sora, L. Laurenti, I. Innocenti, F. Autore, M. A. Limongiello, A. Fresa, A. Bacigalupo, S. Sica
Bone Marrow Transplantation, 2023
Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic Transplant
Fulvia Fanelli, Stefan Hohaus, Maria Cantonetti, Giuseppe Cimino, Elsa Pennese, Roberta Battistini, Eugenio Galli, Raffaella Cerretti, Anna Proia, Federica Fatone, Ida Provenzano, Elisabetta Abruzzese, Erica Finolezzi, Alessandro Pulsoni, Luigi Rigacci
Chemotherapy, 2023
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion
Elisabetta Metafuni, Antonella Cingolani, Massimo Fantoni, Patrizia Chiusolo, Sabrina Giammarco, Federica Sorà, Eugenio Galli, Stefan Hohaus, Francesco D’Alò, Silvia Bellesi, Elena Maiolo, Eleonora Alma, Luca Laurenti, Idanna Innocenti, Francesco Autore, Maria Assunta Limongiello, Rosaria Santangelo, Simona Marchetti, Rosalba Ricci, Simona Sica
Hematological Oncology, 2023
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells
Eugenio Galli, Federica Sorà, Stefan Hohaus, Alberto Fresa, Ilaria Pansini, Francesco Autore, Elisabetta Metafuni, Idanna Innocenti, Maria Assunta Limongiello, Sabrina Giammarco, Luca Laurenti, Andrea Bacigalupo, Patrizia Chiusolo, Valerio De Stefano, Simona Sica
British Journal of Haematology, 2023
PD-L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma
Annarosa Cuccaro, Silvia Bellesi, Eugenio Galli, Ilaria Zangrilli, Francesco Corrente, Elisa Cupelli, Federica Fatone, Elena Maiolo, Eleonora Alma, Marcello Viscovo, Francesco D'Alò, Salvatore Annunziata, Maurizio Martini, Vittoria Rufini, Alessandro Giordano, Valerio De Stefano, Luigi Maria Larocca, Stefan Hohaus
Journal of Leukocyte Biology, 2022
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics
Idanna Innocenti, Annamaria Tomasso, Giulia Benintende, Francesco Autore, Alberto Fresa, Florenzia Vuono, Luca Stirparo, Eugenio Galli, Giovanni D’Arena, Federica Sorà, Dimitar Efremov, Luca Laurenti
Hematological Oncology, 2022
Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation
Marco Cioce, Stefano Botti, Franziska Michaela Lohmeyer, Eugenio Galli, Marinella Magini, Alessandra Giraldi, Paola Garau, Danilo Celli, Maurizio Zega, Simona Sica, Andrea Bacigalupo, Valerio De Stefano, Ivan Borrelli, Umberto Moscato
International Journal of Hematology, 2022
Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant
Federica Sora, Sabrina Giammarco, Anna Maria Raiola, Carmen Di Grazia, Stefania Bregante, Francesca Gualandi, Riccardo Varaldo, Patrizia Chiusolo, Simona Sica, Luca Laurenti, Idanna Innocenti, Francesco Autore, Elisabetta Metafuni, Eugenio Galli, Andrea Bacigalupo, Emanuele Angelucci
Blood Cancer Journal, 2022
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study
Livio Pagano, Marianna Criscuolo, Alessandro Broccoli, Alfonso Piciocchi, Marzia Varettoni, Eugenio Galli, Antonella Anastasia, Maria Cantonetti, Livio Trentin, Sofia Kovalchuk, Lorella Orsucci, Annamaria Frustaci, Angelica Spolzino, Stefano Volpetti, Ombretta Annibali, Sergio Storti, Caterina Stelitano, Francesco Marchesi, Massimo Offidani, Beatrice Casadei, Maria Elena Nizzoli, Maria Lucia De Luca, Luana Fianchi, Marina Motta, Luca Guarnera, Edoardo Simonetti, Andrea Visentin, Francesco Vassallo, Marina Deodato, Chiara Sarlo, Attilio Olivieri, Brunangelo Falini, Alessandro Pulsoni, Enrico Tiacci, Pier Luigi Zinzani
Blood Cancer Journal, 2022
Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia
Eugenio Galli, Federica Sorà, Luca Di Gianfrancesco, Sabrina Giammarco, Elisabetta Metafuni, Maria Assunta Limongiello, Idanna Innocenti, Francesco Autore, Luca Laurenti, Patrizia Chiusolo, Andrea Bacigalupo, Simona Sica
Supportive Care in Cancer, 2022
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma
Eugenio Galli, Federica Sorà, Stefan Hohaus, Silvia Bellesi, Francesco Autore, Elisabetta Metafuni, Idanna Innocenti, John Marra, Alberto Fresa, Maria Assunta Limongiello, Sabrina Giammarco, Lucia Leccisotti, Andrea Guarneri, Patrizia Chiusolo, Luca Laurenti, Luciana Teofili, Nicola Piccirillo, Andrea Bacigalupo, Simona Sica
Bone Marrow Transplantation, 2022
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants
Eugenio Galli, Elisabetta Metafuni, Sabrina Giammarco, Maria Assunta Limongiello, Idanna Innocenti, Francesco Autore, Luca Laurenti, Federica Sorà, Patrizia Chiusolo, Luciana Teofili, Andrea Bacigalupo, Simona Sica
Bone Marrow Transplantation, 2022
Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma
Raphaël Liévin, Roberta Di Blasi, Florence Morin, Eugenio Galli, Vincent Allain, Romain De Jorna, Laetitia Vercellino, Nathalie Parquet, Miryam Mebarki, Jerome Larghero, Eric de Kerviler, Isabelle Madelaine, Sophie Caillat-Zucman, Sylvie Chevret, Catherine Thieblemont
Bone Marrow Transplantation, 2022
Treatment options for elderly/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: A comprehensive review
Alberto Fresa, Francesco Autore, Eugenio Galli, Annamaria Tomasso, Luca Stirparo, Idanna Innocenti, Luca Laurenti
Journal of Clinical Medicine, 2021
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review
Federica Sora, Mario Annunziata, Luca Laurenti, Sabrina Giammarco, Patrizia Chiusolo, Idanna Innocenti, Francesco Autore, Elisabetta Metafuni, Eugenio Galli, Andrea Bacigalupo, Felicetto Ferrara, Simona Sica
Pediatric Blood and Cancer, 2021
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021
Andrea Bacigalupo, Idanna Innocenti, Elena Rossi, Federica Sora, Eugenio Galli, Francesco Autore, Elisabetta Metafuni, Patrizia Chiusolo, Sabrina Giammarco, Luca Laurenti, Giulia Benintende, Simona Sica, Valerio De Stefano
Frontiers in Immunology, 2021
Is allogeneic transplantation an option in patients affected by concurrent myelofibrosis and chronic myeloid leukemia (CML)?
Federica Sorà, Patrizia Chiusolo, Francesco Autore, Sabrina Giammarco, Luca Laurenti, Elisabetta Metafuni, Idanna Innocenti, Eugenio Galli, Andrea Bacigalupo, Simona Sica
Mediterranean Journal of Hematology and Infectious Diseases, 2021
Cytomorphology of chimeric antigen receptor T-cells (CAR-T)
Eugenio Galli, Silvia Bellesi, Marcello Viscovo, Federica Sorà, Stefan Hohaus, Nicola Piccirillo, Luca Laurenti, Patrizia Chiusolo, Valerio De Stefano, Simona Sica, Gina Zini
Mediterranean Journal of Hematology and Infectious Diseases, 2021
G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma
Eugenio Galli, Vincent Allain, Roberta Di Blasi, Sophie Bernard, Laetitia Vercellino, Florence Morin, Hannah Moatti, Sophie Caillat-Zucman, Sylvie Chevret, Catherine Thieblemont
Bone Marrow Transplantation, 2020
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Laetitia Vercellino, Roberta Di Blasi, Salim Kanoun, Benoit Tessoulin, Cedric Rossi, Maud D'Aveni-Piney, Lucie Obéric, Caroline Bodet-Milin, Pierre Bories, Pierre Olivier, Ingrid Lafon, Alina Berriolo-Riedinger, Eugenio Galli, Sophie Bernard, Marie-Thérèse Rubio, Celine Bossard, Veronique Meignin, Pascal Merlet, Pierre Feugier, Steven Le Gouill, Loic Ysebaert, Olivier Casasnovas, Michel Meignan, Sylvie Chevret, Catherine Thieblemont
Blood Advances, 2020
Comorbidity assessment to determine prognosis in older adult patients with classical Hodgkin lymphoma
Eugenio Galli, Annarosa Cuccaro, Elena Maiolo, Silvia Bellesi, Francesco D'Alò, Domenico Fusco, Giuseppe Colloca, Valerio De Stefano, Stefan Hohaus
Hematological Oncology, 2020
Aggressive Light Chain Myeloma Originating a Double Peak on Serum Electrophoresis: What's Underneath?
Eugenio Galli, Marianna Criscuolo, Luana Fianchi, Umberto Basile, Livio Pagano
Acta Haematologica, 2020
Burkitt lymphoma as fourth neoplasia in a patient affected by cowden syndrome with a novel PTEN germline pathogenic variant
Eugenio Galli, Francesco D’Alò, Annarosa Cuccaro, Eleonora Alma, Elena Maiolo, Fulvia Brugnoletti, Luigi Maria Larocca, Marcella Zollino, Andrea Paolo Bacigalupo, Stefan Hohaus
Mediterranean Journal of Hematology and Infectious Diseases, 2020
Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients
Elisa Ferretti, Stefan Hohaus, Arianna Di Napoli, Beatrice Belmonte, Annarosa Cuccaro, Elisa Cupelli, Eugenio Galli, Vittoria Rufini, Gino Tripodi, Giulio Fraternali-Orcioni, Vito Pistoia, Anna Corcione
Oncotarget, 2017
CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma
Annarosa Cuccaro, Salvatore Annunziata, Elisa Cupelli, Maurizio Martini, Maria L. Calcagni, Vittoria Rufini, Manuela Giachelia, Francesca Bartolomei, Eugenio Galli, Francesco D'Alò, Maria T. Voso, Giuseppe Leone, Alessandro Giordano, Luigi M. Larocca, Stefan Hohaus
Cancer Medicine, 2016
Prognostic factors in Hodgkin lymphoma
Annarosa Cuccaro, Francesca Bartolomei, Elisa Cupelli, Stefan Hohaus
Mediterranean Journal of Hematology and Infectious Diseases, 2014

Eugenio Galli

EDUCATION

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS